BCHE and Alzheimer disease: As thedisease advances, BChE activity rises, further contributing to AChdepletion.−,  Thus, inhibiting BChE to enhance the level of AChhas gained importance as an alternative therapeutic target for managingsymptoms and slowing AD progression. Also,BChE has been reported to slow the formation of Aβ fibrils byacting as a molecular chaperone, stabilizing soluble Aβ groups. From this point of view, it is thought thatcompounds that inhibit BChE by binding to both the catalytic activesite (CAS) and the PAS region can prevent Aβ-associated toxicitywhile simultaneously reducing ACh hydrolysis.